As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.
An additional six months of data from a late-stage trial of Takeda Pharmaceutical Co.’s experimental dengue vaccine again showed TAK-003 failed to protect against one of the four types of the virus in an important patient group, researchers said.
The Philippine Department of Justice has found probable cause to indict officials from French drugmaker Sanofi and former and current Philippine health officials over 10 deaths the department said were linked to use of a dengue vaccine.
